Uncategorized

Allegro Ophthalmics Announces Issuance of U.S. Patent for First-in-Class Integrin Peptide Therapy Candidate Luminate®

by Business Wire • 2015/05/18 • 0 Comments

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, announced that the USPTO has issued US Patent 9,018,352 covering the composition of matter of Allegro’s product candidate Luminate (ALG-1001).

← Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group.

VIDEO: Speaker highlights new data on OCT in glaucoma →

Post navigation